The African medicines regulatory harmonization initiative: Rationale and benefits

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 2, 2011, Pages 176-178

  Ndomondo Sigonda, M ^a   Ambali, A ^a  

^a African Union NEPAD Agency   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

MICONAZOLE;

AFRICA; AFRICAN MEDICINE; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; ECONOMIC DEVELOPMENT; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NATIONAL HEALTH SERVICE; OROPHARYNX CANDIDIASIS; PATIENT SAFETY; PRIORITY JOURNAL; PROTECTION; PUBLIC HEALTH SERVICE; REGISTRATION; RESOURCE ALLOCATION; REVIEW; SOCIOECONOMICS; WORLD HEALTH ORGANIZATION;

AFRICA; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; HEALTH POLICY; HUMANS; PUBLIC HEALTH;

EID: 78951481365     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.299     Document Type: Review

References (4)

1. WHO/AFRO/EDP. Availability of Drug Regulatory and Quality Assurance Elements in Member States of the WHO African Region. Brazzaville, Congo, 2004.
2. Matsoso, P. Harmonising Drug Regulation in Africa (2006).
3. Roey, J.V. & Haxaire, M. The need to reform current registration processes to improve access to essential medicines in developing countries. Pharm. Med. 22, 207-213 (2008).
4. 14th African Union Assembly Decision, Assembly/AU/14 (XIV), February 2010.